25 XP   0   0   10

Memphasys Ltd
Buy, Hold or Sell?

Let's analyse Memphasys together

PenkeI guess you are interested in Memphasys Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Memphasys Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Memphasys Ltd

I send you an email if I find something interesting about Memphasys Ltd.

Quick analysis of Memphasys (30 sec.)










What can you expect buying and holding a share of Memphasys? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
A$0.00
Expected worth in 1 year
A$0.00
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$0.00
Return On Investment
-54.2%

For what price can you sell your share?

Current Price per Share
A$0.01
Expected price per share
A$0.009 - A$0.011
How sure are you?
50%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1. Valuation of Memphasys (5 min.)




Live pricePrice per Share (EOD)

A$0.01

Intrinsic Value Per Share

A$-0.02 - A$-0.01

Total Value Per Share

A$-0.02 - A$0.00

2. Growth of Memphasys (5 min.)




Is Memphasys growing?

Current yearPrevious yearGrowGrow %
How rich?$4.7m$4.9m-$170.1k-3.5%

How much money is Memphasys making?

Current yearPrevious yearGrowGrow %
Making money-$2.2m-$1.3m-$858.2k-38.8%
Net Profit Margin-22,136.6%-7,668.9%--

How much money comes from the company's main activities?

3. Financial Health of Memphasys (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#777 / 1050

Most Revenue
#688 / 1050

Most Profit
#325 / 1050

Most Efficient
#995 / 1050
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

What can you expect buying and holding a share of Memphasys? (5 min.)

Welcome investor! Memphasys's management wants to use your money to grow the business. In return you get a share of Memphasys.

What can you expect buying and holding a share of Memphasys?

First you should know what it really means to hold a share of Memphasys. And how you can make/lose money.

Speculation

The Price per Share of Memphasys is A$0.009. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Memphasys.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Memphasys, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.00. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Memphasys.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-13.3%0.00-13.3%0.00-11.2%0.00-8.8%0.00-10.4%
Usd Book Value Change Per Share0.00-12.1%0.00-12.1%0.00-5.2%0.002.2%0.00-0.9%
Usd Dividend Per Share0.003.3%0.003.3%0.000.4%0.004.0%0.002.0%
Usd Total Gains Per Share0.00-8.8%0.00-8.8%0.00-4.8%0.006.2%0.001.1%
Usd Price Per Share0.01-0.01-0.03-0.03-0.02-
Price to Earnings Ratio-7.90--7.90--28.21--43.20--26.39-
Price-to-Total Gains Ratio-11.97--11.97--66.32-0.05-2.61-
Price to Book Ratio3.64-3.64-7.68-7.55-0.96-
Price-to-Total Gains Ratio-11.97--11.97--66.32-0.05-2.61-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0058491
Number of shares170966
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (170966 shares)-135.4795.34
Gains per Year (170966 shares)-541.88381.38
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1205-747-552247135371
2410-1494-1094493269752
3615-2240-16367404041133
4820-2987-21789875391514
51024-3734-272012336741895
61229-4481-326214808082276
71434-5227-380417269432657
81639-5974-4346197310783038
91844-6721-4888222012133419
102049-7468-5430246613473800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%1.015.01.05.9%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%2.03.00.040.0%5.05.00.050.0%8.09.00.047.1%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%4.00.06.040.0%4.00.013.023.5%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%3.02.00.060.0%6.04.00.060.0%9.08.00.052.9%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

Fundamentals of Memphasys

About Memphasys Ltd

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company's product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.

Fundamental data was last updated by Penke on 2024-02-18 02:52:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.1. Profitability of Memphasys Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Memphasys earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • A Net Profit Margin of -22,136.6% means that $-221.37 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Memphasys Ltd:

  • The MRQ is -22,136.6%. The company is making a huge loss. -2
  • The TTM is -22,136.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-22,136.6%TTM-22,136.6%0.0%
TTM-22,136.6%YOY-7,668.9%-14,467.7%
TTM-22,136.6%5Y-7,056.2%-15,080.4%
5Y-7,056.2%10Y-4,073.2%-2,982.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22,136.6%-172.8%-21,963.8%
TTM-22,136.6%-213.8%-21,922.8%
YOY-7,668.9%-292.1%-7,376.8%
5Y-7,056.2%-479.2%-6,577.0%
10Y-4,073.2%-636.2%-3,437.0%
1.1.2. Return on Assets

Shows how efficient Memphasys is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • -23.2% Return on Assets means that Memphasys generated $-0.23 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Memphasys Ltd:

  • The MRQ is -23.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -23.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-23.2%TTM-23.2%0.0%
TTM-23.2%YOY-14.7%-8.5%
TTM-23.2%5Y-14.5%-8.6%
5Y-14.5%10Y-23.4%+8.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-23.2%-12.5%-10.7%
TTM-23.2%-12.2%-11.0%
YOY-14.7%-11.3%-3.4%
5Y-14.5%-13.7%-0.8%
10Y-23.4%-15.4%-8.0%
1.1.3. Return on Equity

Shows how efficient Memphasys is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • -46.1% Return on Equity means Memphasys generated $-0.46 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Memphasys Ltd:

  • The MRQ is -46.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -46.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-46.1%TTM-46.1%0.0%
TTM-46.1%YOY-27.2%-18.8%
TTM-46.1%5Y-23.7%-22.4%
5Y-23.7%10Y-64.1%+40.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.1%-16.2%-29.9%
TTM-46.1%-15.9%-30.2%
YOY-27.2%-14.4%-12.8%
5Y-23.7%-18.9%-4.8%
10Y-64.1%-19.8%-44.3%
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.2. Operating Efficiency of Memphasys Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Memphasys is operating .

  • Measures how much profit Memphasys makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • An Operating Margin of -20,075.7% means the company generated $-200.76  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Memphasys Ltd:

  • The MRQ is -20,075.7%. The company is operating very inefficient. -2
  • The TTM is -20,075.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-20,075.7%TTM-20,075.7%0.0%
TTM-20,075.7%YOY-6,001.6%-14,074.2%
TTM-20,075.7%5Y-6,291.9%-13,783.9%
5Y-6,291.9%10Y-3,533.8%-2,758.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-20,075.7%-299.5%-19,776.2%
TTM-20,075.7%-222.2%-19,853.5%
YOY-6,001.6%-296.8%-5,704.8%
5Y-6,291.9%-469.0%-5,822.9%
10Y-3,533.8%-617.8%-2,916.0%
1.2.2. Operating Ratio

Measures how efficient Memphasys is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 237.41 means that the operating costs are $237.41 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Memphasys Ltd:

  • The MRQ is 237.407. The company is inefficient in keeping operating costs low. -1
  • The TTM is 237.407. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ237.407TTM237.4070.000
TTM237.407YOY101.680+135.727
TTM237.4075Y82.403+155.004
5Y82.40310Y45.329+37.074
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ237.4072.914+234.493
TTM237.4073.255+234.152
YOY101.6803.885+97.795
5Y82.4036.009+76.394
10Y45.3297.652+37.677
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.3. Liquidity of Memphasys Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Memphasys is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.40 means the company has $0.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Memphasys Ltd:

  • The MRQ is 0.404. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.404. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.404TTM0.4040.000
TTM0.404YOY0.447-0.043
TTM0.4045Y2.832-2.428
5Y2.83210Y1.679+1.153
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4044.017-3.613
TTM0.4044.478-4.074
YOY0.4475.591-5.144
5Y2.8326.256-3.424
10Y1.6796.562-4.883
1.3.2. Quick Ratio

Measures if Memphasys is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • A Quick Ratio of 0.14 means the company can pay off $0.14 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Memphasys Ltd:

  • The MRQ is 0.143. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.143. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.143TTM0.1430.000
TTM0.143YOY0.086+0.058
TTM0.1435Y1.509-1.365
5Y1.50910Y0.998+0.510
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1433.585-3.442
TTM0.1434.182-4.039
YOY0.0865.485-5.399
5Y1.5096.116-4.607
10Y0.9986.375-5.377
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

1.4. Solvency of Memphasys Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Memphasys assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Memphasys to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.50 means that Memphasys assets are financed with 49.7% credit (debt) and the remaining percentage (100% - 49.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Memphasys Ltd:

  • The MRQ is 0.497. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.497. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.497TTM0.4970.000
TTM0.497YOY0.459+0.038
TTM0.4975Y0.323+0.174
5Y0.32310Y0.570-0.247
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4970.332+0.165
TTM0.4970.331+0.166
YOY0.4590.262+0.197
5Y0.3230.370-0.047
10Y0.5700.380+0.190
1.4.2. Debt to Equity Ratio

Measures if Memphasys is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Memphasys to the Biotechnology industry mean.
  • A Debt to Equity ratio of 98.6% means that company has $0.99 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Memphasys Ltd:

  • The MRQ is 0.986. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.986. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.986TTM0.9860.000
TTM0.986YOY0.847+0.140
TTM0.9865Y0.562+0.424
5Y0.56210Y1.511-0.948
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.9860.375+0.611
TTM0.9860.396+0.590
YOY0.8470.317+0.530
5Y0.5620.423+0.139
10Y1.5110.477+1.034
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

2. Market Valuation of Memphasys Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Memphasys generates.

  • Above 15 is considered overpriced but always compare Memphasys to the Biotechnology industry mean.
  • A PE ratio of -7.90 means the investor is paying $-7.90 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Memphasys Ltd:

  • The EOD is -4.871. Based on the earnings, the company is expensive. -2
  • The MRQ is -7.902. Based on the earnings, the company is expensive. -2
  • The TTM is -7.902. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.871MRQ-7.902+3.031
MRQ-7.902TTM-7.9020.000
TTM-7.902YOY-28.207+20.305
TTM-7.9025Y-43.202+35.300
5Y-43.20210Y-26.387-16.815
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.871-2.631-2.240
MRQ-7.902-2.224-5.678
TTM-7.902-2.796-5.106
YOY-28.207-4.390-23.817
5Y-43.202-6.123-37.079
10Y-26.387-6.245-20.142
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Memphasys Ltd:

  • The EOD is -5.134. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.328. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.328. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.134MRQ-8.328+3.194
MRQ-8.328TTM-8.3280.000
TTM-8.328YOY-17.839+9.511
TTM-8.3285Y-21.111+12.783
5Y-21.11110Y-21.140+0.029
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.134-3.503-1.631
MRQ-8.328-2.905-5.423
TTM-8.328-3.541-4.787
YOY-17.839-6.014-11.825
5Y-21.111-8.355-12.756
10Y-21.140-8.755-12.385
3rd Party Ad. No recommendation by Penke. PLUS is ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Memphasys is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 3.64 means the investor is paying $3.64 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Memphasys Ltd:

  • The EOD is 2.245. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.641. Based on the equity, the company is fair priced.
  • The TTM is 3.641. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.245MRQ3.641-1.397
MRQ3.641TTM3.6410.000
TTM3.641YOY7.680-4.039
TTM3.6415Y7.553-3.912
5Y7.55310Y0.959+6.594
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.2452.137+0.108
MRQ3.6411.877+1.764
TTM3.6412.117+1.524
YOY7.6803.059+4.621
5Y7.5533.595+3.958
10Y0.9593.961-3.002
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Memphasys Ltd.

3rd Party Ad. No recommendation by Penke. PLUS is ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Memphasys Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.002-0.0020%-0.001-57%0.000-654%0.000-93%
Book Value Per Share--0.0040.0040%0.006-30%0.005-27%0.003+32%
Current Ratio--0.4040.4040%0.447-10%2.832-86%1.679-76%
Debt To Asset Ratio--0.4970.4970%0.459+8%0.323+54%0.570-13%
Debt To Equity Ratio--0.9860.9860%0.847+16%0.562+75%1.511-35%
Dividend Per Share--0.0000.0000%0.000+726%0.001-17%0.000+66%
Eps---0.002-0.0020%-0.002-16%-0.001-34%-0.001-22%
Free Cash Flow Per Share---0.002-0.0020%-0.002+40%-0.002+15%-0.002-12%
Free Cash Flow To Equity Per Share--0.0000.0000%-0.002+692%0.000+270%0.000+11%
Gross Profit Margin--1.0441.0440%1.051-1%1.019+2%1.014+3%
Intrinsic Value_10Y_max---0.008--------
Intrinsic Value_10Y_min---0.025--------
Intrinsic Value_1Y_max---0.001--------
Intrinsic Value_1Y_min---0.002--------
Intrinsic Value_3Y_max---0.004--------
Intrinsic Value_3Y_min---0.007--------
Intrinsic Value_5Y_max---0.006--------
Intrinsic Value_5Y_min---0.012--------
Market Cap12094739.712-122%26888522.71526888522.7150%58726680.602-54%61755294.587-56%45404773.548-41%
Net Profit Margin---221.366-221.3660%-76.689-65%-70.562-68%-40.732-82%
Operating Margin---200.757-200.7570%-60.016-70%-62.919-69%-35.338-82%
Operating Ratio--237.407237.4070%101.680+133%82.403+188%45.329+424%
Pb Ratio2.245-62%3.6413.6410%7.680-53%7.553-52%0.959+280%
Pe Ratio-4.871+38%-7.902-7.9020%-28.207+257%-43.202+447%-26.387+234%
Price Per Share0.009-62%0.0150.0150%0.044-67%0.044-67%0.033-55%
Price To Free Cash Flow Ratio-5.134+38%-8.328-8.3280%-17.839+114%-21.111+153%-21.140+154%
Price To Total Gains Ratio-7.382+38%-11.975-11.9750%-66.324+454%0.046-26055%2.612-558%
Quick Ratio--0.1430.1430%0.086+67%1.509-91%0.998-86%
Return On Assets---0.232-0.2320%-0.147-36%-0.145-37%-0.234+1%
Return On Equity---0.461-0.4610%-0.272-41%-0.237-49%-0.641+39%
Total Gains Per Share---0.001-0.0010%-0.001-46%0.001-242%0.000-870%
Usd Book Value--4799309.3814799309.3810%4969482.447-3%5129714.512-6%2836563.159+69%
Usd Book Value Change Per Share---0.001-0.0010%0.000-57%0.000-654%0.000-93%
Usd Book Value Per Share--0.0030.0030%0.004-30%0.004-27%0.002+32%
Usd Dividend Per Share--0.0000.0000%0.000+726%0.000-17%0.000+66%
Usd Eps---0.001-0.0010%-0.001-16%-0.001-34%-0.001-22%
Usd Free Cash Flow---2098332.780-2098332.7800%-2139449.353+2%-1904402.230-9%-1425023.057-32%
Usd Free Cash Flow Per Share---0.001-0.0010%-0.002+40%-0.001+15%-0.001-12%
Usd Free Cash Flow To Equity Per Share--0.0000.0000%-0.001+692%0.000+270%0.000+11%
Usd Market Cap7860371.339-122%17474850.91217474850.9120%38166469.723-54%40134765.952-56%29508562.329-41%
Usd Price Per Share0.006-62%0.0090.0090%0.028-67%0.028-67%0.021-55%
Usd Profit---2211361.438-2211361.4380%-1353068.404-39%-1174932.373-47%-1314990.113-41%
Usd Revenue--9989.6139989.6130%17643.485-43%9055.317+10%76305.539-87%
Usd Total Gains Per Share---0.001-0.0010%0.000-46%0.001-242%0.000-870%
 EOD+3 -5MRQTTM+0 -0YOY+11 -255Y+8 -2810Y+13 -23

4.2. Fundamental Score

Let's check the fundamental score of Memphasys Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.871
Price to Book Ratio (EOD)Between0-12.245
Net Profit Margin (MRQ)Greater than0-221.366
Operating Margin (MRQ)Greater than0-200.757
Quick Ratio (MRQ)Greater than10.143
Current Ratio (MRQ)Greater than10.404
Debt to Asset Ratio (MRQ)Less than10.497
Debt to Equity Ratio (MRQ)Less than10.986
Return on Equity (MRQ)Greater than0.15-0.461
Return on Assets (MRQ)Greater than0.05-0.232
Total2/10 (20.0%)

4.3. Technical Score

Let's check the technical score of Memphasys Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5043.260
Ma 20Greater thanMa 500.010
Ma 50Greater thanMa 1000.011
Ma 100Greater thanMa 2000.011
OpenGreater thanClose0.009
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets14,668
Total Liabilities7,283
Total Stockholder Equity7,385
 As reported
Total Liabilities 7,283
Total Stockholder Equity+ 7,385
Total Assets = 14,668

Assets

Total Assets14,668
Total Current Assets2,249
Long-term Assets12,419
Total Current Assets
Cash And Cash Equivalents 638
Short-term Investments 43
Net Receivables 117
Inventory 131
Other Current Assets 1,363
Total Current Assets  (as reported)2,249
Total Current Assets  (calculated)2,291
+/- 43
Long-term Assets
Property Plant Equipment 2,098
Long Term Investments 26
Intangible Assets 10,295
Long-term Assets  (as reported)12,419
Long-term Assets  (calculated)12,419
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities5,567
Long-term Liabilities1,716
Total Stockholder Equity7,385
Total Current Liabilities
Short-term Debt 4,658
Short Long Term Debt 4,547
Accounts payable 115
Other Current Liabilities 5,452
Total Current Liabilities  (as reported)5,567
Total Current Liabilities  (calculated)14,772
+/- 9,204
Long-term Liabilities
Long term Debt Total 1,715
Other Liabilities 1
Long-term Liabilities  (as reported)1,716
Long-term Liabilities  (calculated)1,716
+/- 0
Total Stockholder Equity
Common Stock53,418
Retained Earnings -46,173
Accumulated Other Comprehensive Income 140
Total Stockholder Equity (as reported)7,385
Total Stockholder Equity (calculated)7,385
+/-0
Other
Capital Stock53,418
Cash and Short Term Investments 638
Common Stock Shares Outstanding 1,841,680
Current Deferred Revenue-4,658
Liabilities and Stockholders Equity 14,668
Net Debt 5,734
Net Invested Capital 11,931
Net Tangible Assets -2,910
Net Working Capital -3,319
Property Plant and Equipment Gross 4,047
Short Long Term Debt Total 6,372



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-30
> Total Assets 
4,463
5,056
5,757
17,717
10,571
8,952
13,632
7,102
6,844
7,194
7,302
4,217
6,836
11,299
14,581
14,121
14,668
14,66814,12114,58111,2996,8364,2177,3027,1946,8447,10213,6328,95210,57117,7175,7575,0564,463
   > Total Current Assets 
0
1,548
1,229
3,570
1,316
781
2,088
882
981
824
4,304
861
2,154
3,558
3,689
2,029
2,249
2,2492,0293,6893,5582,1548614,3048249818822,0887811,3163,5701,2291,5480
       Cash And Cash Equivalents 
209
696
33
1,201
29
173
181
84
175
19
2
202
874
1,968
2,003
269
638
6382692,0031,96887420221917584181173291,20133696209
       Short-term Investments 
0
0
0
0
0
0
0
0
38
43
3,825
0
0
0
0
0
43
43000003,825433800000000
       Net Receivables 
167
445
864
1,899
826
213
432
234
19
277
53
593
96
166
14
119
117
117119141669659353277192344322138261,899864445167
       Other Current Assets 
40
33
39
83
34
24
1,075
263
775
485
424
659
1,151
1,391
1,567
1,553
1,363
1,3631,5531,5671,3911,1516594244857752631,075243483393340
   > Long-term Assets 
0
3,508
4,527
14,147
9,255
8,170
11,544
6,221
5,863
6,370
2,998
3,356
4,683
7,741
10,892
12,093
12,419
12,41912,09310,8927,7414,6833,3562,9986,3705,8636,22111,5448,1709,25514,1474,5273,5080
       Property Plant Equipment 
2,275
1,786
1,687
1,373
1,564
1,183
6,827
425
68
62
41
23
28
1,195
2,601
2,340
2,098
2,0982,3402,6011,19528234162684256,8271,1831,5641,3731,6871,7862,275
       Goodwill 
0
0
0
0
0
0
0
1,545
339
339
339
0
0
0
0
0
0
0000003393393391,5450000000
       Long Term Investments 
0
0
0
0
0
0
0
4,125
3,825
3,825
0
0
0
0
0
74
26
2674000003,8253,8254,1250000000
       Intangible Assets 
0
0
1,986
12,325
7,391
6,687
3,885
1,671
1,971
2,483
2,956
3,333
4,655
6,546
8,291
9,679
10,295
10,2959,6798,2916,5464,6553,3332,9562,4831,9711,6713,8856,6877,39112,3251,98600
       Long-term Assets Other 
0
867
0
0
0
0
531
0
0
0
0
3,356
4,683
-7,741
-10,892
-12,093
-12,419
-12,419-12,093-10,892-7,7414,6833,356000053100008670
> Total Liabilities 
2,663
3,954
6,155
4,874
3,576
4,389
6,642
8,095
6,098
5,717
7,704
866
765
1,543
5,974
6,475
7,283
7,2836,4755,9741,5437658667,7045,7176,0988,0956,6424,3893,5764,8746,1553,9542,663
   > Total Current Liabilities 
1,616
2,715
4,533
2,126
3,132
4,302
3,668
1,787
3,260
5,648
6,661
823
733
587
857
4,539
5,567
5,5674,5398575877338236,6615,6483,2601,7873,6684,3023,1322,1264,5332,7151,616
       Short-term Debt 
0
0
0
100
0
1,068
479
480
2,586
4,843
5,745
475
323
136
269
3,659
4,658
4,6583,6592691363234755,7454,8432,5864804791,0680100000
       Short Long Term Debt 
0
0
0
0
0
0
0
6,716
2,166
4,840
5,741
472
319
26
181
3,561
4,547
4,5473,561181263194725,7414,8402,1666,7160000000
       Accounts payable 
910
1,137
1,858
1,015
1,616
1,684
1,849
627
245
430
335
130
227
219
159
132
115
1151321592192271303354302456271,8491,6841,6161,0151,8581,137910
       Other Current Liabilities 
706
1,579
2,196
658
1,516
1,549
1,340
680
429
374
581
218
182
-3
698
4,408
5,452
5,4524,408698-31822185813744296801,3401,5491,5166582,1961,579706
   > Long-term Liabilities 
0
1,239
1,622
2,748
444
88
2,974
6,308
2,838
69
1,043
42
32
956
5,117
1,935
1,716
1,7161,9355,11795632421,043692,8386,3082,974884442,7481,6221,2390
       Long term Debt Total 
0
0
0
0
0
0
0
0
2,785
43
1,021
7
3
931
4,857
1,825
1,715
1,7151,8254,857931371,021432,78500000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
-100
0
-1,068
-479
-480
-2,586
-4,827
-5,731
-465
-316
905
1,743
-1,735
-2,832
-2,832-1,7351,743905-316-465-5,731-4,827-2,586-480-479-1,0680-100000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
26
22
0
0
0
0
0
0
0000002226000000000
> Total Stockholder Equity
1,800
1,101
-398
12,843
6,995
4,562
1,823
-993
747
1,478
-402
3,352
6,071
9,756
8,607
7,647
7,385
7,3857,6478,6079,7566,0713,352-4021,478747-9931,8234,5626,99512,843-3981,1011,800
   Retained Earnings -46,173-42,771-41,167-39,681-38,804-37,759-37,358-35,358-33,053-30,407-26,565-22,307-15,999-9,678-12,969-10,4430
   Accumulated Other Comprehensive Income 
0
943
1,549
1,161
1,103
1,042
588
69
217
926
936
1,016
1,451
739
890
76
140
140768907391,4511,016936926217695881,0421,1031,1611,5499430
   Capital Surplus 00000000000000000
   Treasury Stock00000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.